多西他赛用于合并有糖尿病的乳腺癌患者化疗的安全性分析

Combined with Docetaxel for Safety Analysis of Breast Cancer Chemotherapy in Patients with Diabetes Mellitus

目的分析多西他赛用于乳腺癌合并糖尿病患者化疗的安全性。方法选取该院收诊的乳腺癌合并糖尿病患者42例,给予多西他赛进行静脉滴注治疗,在治疗过程中,不给予粒细胞集落刺激因子,分析化疗的安全性。结果该组42例患者,CR 4例,PR 14例,NC 18例,PD 6例,RR 42.86%,CBR 85.71%。治疗前、治疗后的Karnofsky评分比较,差异无统计学意义(P>0.05)。可以评价不良反应的患者有40例,粒细胞减少、白细胞减少、脱发、呕吐、腹泻、血小板减少Ⅲ、Ⅳ度不良反应发生率分别为57.50%、45.00%、5.00%、5.00%、2.50%、2.50%。结论多西他赛是一种乳腺癌治疗效果较好的化疗药物,在严密的观测以及合理的降糖药物使用下,对合并糖尿病的乳腺癌患者是安全的。

Objective To analyze the efficacy and safety of docetaxel for patients with breast cancer combined with diabetes. Methods Select our hospital received diagnosis of breast carcinoma in patients with diabetes mellitus patients 42 cases, treated with docetaxel intravenous drip treatment, in the course of treatment, do not give granulocyte colony stimulating factor, analysis of the safety of chemotherapy. Results In this group, 42 patients, CR 4, PR 14, NC 18, PD 6, RR 42.86%,CBR 85.71%. Before treatment, after treatment, the Karnofsky score was not statistically significant（P〈0.05）. Adverse reactions can be evaluated in 40 patients, the reduction of granulocyte, white blood cells, hair loss, vomiting, diarrhea, blood platelets to reduce Ⅲ, Ⅳ degrees of adverse reactions were 57.50%, 5%, 5%, 2.50%, 2.50%, 45%. Conclusion Docetaxel is a breast cancer treatment effect better chemotherapeutic drugs, under strict observation and reasonable application of hypoglycemic agents, for patients with type 2 diabetes and breast cancer patients is safe.